The Experts below are selected from a list of 864 Experts worldwide ranked by ideXlab platform
Wen Tan - One of the best experts on this subject based on the ideXlab platform.
-
Design, synthesis and biological evaluation of Bambuterol analogues as novel inhibitors of butyrylcholinesterase.
European journal of medicinal chemistry, 2016Co-Authors: Yiguang Tian, Marco Pistolozzi, Shanping Wang, Ya Jin, Ting Zhou, Gaurab Roy, Wen TanAbstract:An increase activity of butyrylcholinesterase is believed to contribute to Alzheimer's disease. Bambuterol is a known potent inhibitor of butyrylcholinesterase, but it has undesired cardiac effects and less lipophilicity. Thirteen Bambuterol analogues were synthesized using 1-(3, 5-dihydroxyphenyl) ethanone as a starting material. In-vitro cholinesterase assay established that the majority of the compounds are specific butyrylcholinesterase inhibitors. Out of the 13 compounds, two Bambuterol derivatives, BD-6 and BD-11 exhibited similar efficacies in inhibiting butyrylcholinesterase with fewer effects on heart and enhanced possibilities of permeating through the blood-brain barrier as compared to Bambuterol. These Bambuterol analogues may provide better alternatives for treatments of Alzheimer's disease.
-
In vivo metabolism study of (R)-Bambuterol in humans using ultra high performance liquid chromatography with tandem mass spectrometry.
Journal of separation science, 2016Co-Authors: Ting Zhou, Shan Liu, Ting Zhao, Dan Zeng, Yang Yang, Wen TanAbstract:(R)-Bambuterol, a selective β2-adrenoceptor agonist, has been approved as a new drug for the treatment of asthma and chronic obstructive pulmonary disease by the China Food and Drug Administration and is currently under phase I clinical trials. In this study, a combined method based on ultra high performance liquid chromatography with triple quadrupole mass spectrometry and ultra high performance liquid chromatography with quadrupole time-of-flight mass spectrometry was employed for the identification of the major metabolites of (R)-Bambuterol in human plasma and urine after an oral dose of 10 mg. The metabolites were separated by gradient elution program and different sample preparation methods were compared. Totally, 12 metabolites of (R)-Bambuterol were identified, including four metabolites in plasma and all 12 metabolites in urine. Among these, four metabolites are reported for the first time. The possible metabolic pathways of (R)-Bambuterol were subsequently proposed. The results indicated that (R)-Bambuterol was metabolized via hydrolysis, demethylation, oxygenation, glucuronidation, and sulfation pathways in vivo. This study revealed that this combined method was accurate and sensitive to identify the possible metabolites and to better understand the metabolism of (R)-Bambuterol in vivo.
-
resolution of rac Bambuterol via diastereoisomeric salt formation with o chloromandelic acid and differences in the enantiomers pharmacodynamical effects in guinea pigs and beagles
Chirality, 2016Co-Authors: Fei Liu, Shanping Wang, Hongjun Wang, Qing Liu, Xinghan Song, Wen TanAbstract:In this study an enantioseparation method for rac-Bambuterol (5-(2-(tert-butylamino)-1-hydroxyethyl)-1,3-phenylene bis(dimethylcarbamate)) via diastereoisomeric salt formation with o-chloromandelic acid was developed. The enantiomeric excess (ee) values and chemical purities of the desired products were confirmed by high-performance liquid chromatography (HPLC) using chiral stationary phase and reverse-phase HPLC analyses, respectively. The ee values and the chemical purities both exceeded 99%. Animal experiments showed that (R)-Bambuterol was a potent inhibitor for histamine-induced asthma reactions. (S)-Bambuterol was ineffective in relaxing the airways. Both enantiomers increased heart rates in beagles. Therefore, replacing rac-Bambuterol with (R)-Bambuterol could be beneficial for asthma patients.
-
Resolution of Rac‐Bambuterol via Diastereoisomeric Salt Formation with o‐Chloromandelic Acid and Differences in the Enantiomers' Pharmacodynamical Effects in Guinea Pigs and Beagles
Chirality, 2016Co-Authors: Liu Fei, Shanping Wang, Hongjun Wang, Qing Liu, Xinghan Song, Wen TanAbstract:In this study an enantioseparation method for rac-Bambuterol (5-(2-(tert-butylamino)-1-hydroxyethyl)-1,3-phenylene bis(dimethylcarbamate)) via diastereoisomeric salt formation with o-chloromandelic acid was developed. The enantiomeric excess (ee) values and chemical purities of the desired products were confirmed by high-performance liquid chromatography (HPLC) using chiral stationary phase and reverse-phase HPLC analyses, respectively. The ee values and the chemical purities both exceeded 99%. Animal experiments showed that (R)-Bambuterol was a potent inhibitor for histamine-induced asthma reactions. (S)-Bambuterol was ineffective in relaxing the airways. Both enantiomers increased heart rates in beagles. Therefore, replacing rac-Bambuterol with (R)-Bambuterol could be beneficial for asthma patients.
-
chiral analysis of Bambuterol its intermediate and active drug in human plasma by liquid chromatography tandem mass spectrometry application to a pharmacokinetic study
Journal of Chromatography B, 2015Co-Authors: Ting Zhou, Jing Zeng, Shan Liu, Ting Zhao, Wen TanAbstract:Abstract A sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) method has been developed for simultaneous chiral analysis of an antiasthma drug Bambuterol, its key intermediate monocarbamate Bambuterol and its active drug terbutaline in human plasma. All samples were extracted with ethyl acetate and separated on an Astec Chirobiotic T column under isocratic elution with a mobile phase consisting of methanol and water with the addition of 20 mm ammonium acetate and 0.005% (v/v) formic acid at 0.6 mL/min. The analytes were detected by a Xevo TQ-S tandem mass spectrometer with positive electrospray ionization in multiple reaction monitoring mode. The established method has high sensitivity with the lower limit of quantifications of 25.00 pg/mL for Bambuterol enantiomers, and 50.00 pg/mL for monocarbamate Bambuterol and terbutaline enantiomers, respectively. The calibration curves for Bambuterol enantiomers were linear in the range of 25.00–2500 pg/mL, and for monocarbamate Bambuterol and terbutaline enantiomers were linear in the range of 50.00–5000 pg/mL. The intra- and inter-day precisions were
Islam M. Mostafa - One of the best experts on this subject based on the ideXlab platform.
-
Amplified anodic electrogenerated chemiluminescence of tris(2,2′-bipyridyl)ruthenium(II) for ultrasensitive detection of Bambuterol: Application to content uniformity testing
Journal of Electroanalytical Chemistry, 2021Co-Authors: Mohamed Ibrahim Halawa, Islam M. MostafaAbstract:Abstract Asthma is one of the most common chronic diseases among children and has affected about 300 million individuals worldwide according to the report of the world health organization. Herein, we present the first electrochemiluminescence (ECL) report for the determination of an important antiasthmatic drug (Bambuterol). It was found that Bambuterol can act as an efficient coreactant for Ru(bpy)32+ ECL via oxidation-reduction pathway. The electrogenerated reducing species from Bambuterol and Ru(bpy)32+ could react together at the surface of gold electrode to generate an intense ECL signal. Based on this new finding, the first ECL study was proposed and optimized for the rapid, highly sensitive, and selective screening of Bambuterol in its pure form with a wide linearity of 10.0 nM - 2.0 μM and an ultra-low detection limit of 1.48 nM. The developed system was applied for assaying Bambuterol in pharmaceutical preparations. Furthermore, the developed system was also utilized to determine the content uniformity of Bambuterol in low dose tablets.
-
amplified anodic electrogenerated chemiluminescence of tris 2 2 bipyridyl ruthenium ii for ultrasensitive detection of Bambuterol application to content uniformity testing
Journal of Electroanalytical Chemistry, 2021Co-Authors: Mohamed Ibrahim Halawa, Islam M. MostafaAbstract:Abstract Asthma is one of the most common chronic diseases among children and has affected about 300 million individuals worldwide according to the report of the world health organization. Herein, we present the first electrochemiluminescence (ECL) report for the determination of an important antiasthmatic drug (Bambuterol). It was found that Bambuterol can act as an efficient coreactant for Ru(bpy)32+ ECL via oxidation-reduction pathway. The electrogenerated reducing species from Bambuterol and Ru(bpy)32+ could react together at the surface of gold electrode to generate an intense ECL signal. Based on this new finding, the first ECL study was proposed and optimized for the rapid, highly sensitive, and selective screening of Bambuterol in its pure form with a wide linearity of 10.0 nM - 2.0 μM and an ultra-low detection limit of 1.48 nM. The developed system was applied for assaying Bambuterol in pharmaceutical preparations. Furthermore, the developed system was also utilized to determine the content uniformity of Bambuterol in low dose tablets.
Bengt Persson - One of the best experts on this subject based on the ideXlab platform.
-
one year safety study with Bambuterol once daily and terbutaline three times daily in 2 12 year old children with asthma
Pediatric Pulmonology, 2000Co-Authors: Jasminka P. Zarkovic, Anna‐leena Kuusela, Marianne Marenk, Grazyna Sandahl, Erkka Valovirta, Bengt PerssonAbstract:The aim of this study was to compare Bambuterol oral solution (10 mg) administered once daily in the evening with terbutaline oral solution (0.075 mg/kg body weight) administered three times daily in 2–5-year-old children and to compare Bambuterol tablets (10 mg or 20 mg) administered once daily in the evening with terbutaline tablets (2.5 mg) administered three times daily in 6–12-year-old children with asthma. The study was of an open, randomized, parallel-group design, and lasted 1 year. The primary objective was to evaluate safety (pulse rate, blood pressure, adverse events, hematology, and clinical chemistry). Plasma terbutaline concentrations were also measured. Evaluation of efficacy (FEV1) was a secondary objective. A total of 141 patients (83 boys, 58 girls) were randomized and treated with the study drugs, i.e., 43 patients in the terbutaline group (30 on oral solution and 13 on tablets) and 98 patients in the Bambuterol group (62 on oral solution and 36 on tablets). A total of 11 patients discontinued the study: 3 were on terbutaline, and 8 were on Bambuterol. There were no clinically important differences between treatment groups regarding pulse rate, or systolic or diastolic blood pressure. There were no clinically important findings in the laboratory tests (hematology and clinical chemistry). Both terbutaline and Bambuterol were well-tolerated, and the reported adverse events were mostly mild or moderate. Mean steady state plasma terbutaline concentrations at the visits ranged between 8.0–11.5 nmol/L in the Bambuterol tablet group and between 10.6–15.2 nmol/L in the terbutaline tablet group. The corresponding values in children on oral solution were 10.3–11.3 nmol/L in the Bambuterol group and 7.5–9.7 nmol/L in the terbutaline group. FEV1 measured in the 6–12-year-old children increased by more than 0.2 L in both treatment groups during the year in the study. In conclusion, Bambuterol tablets or oral solution once daily and terbutaline tablets or oral solution three times daily showed a comparable and favorable safety profile. Pediatr Pulmonol. 2000; 29:424–429. © 2000 Wiley-Liss, Inc.
-
comparative study using oral solutions of Bambuterol once daily or terbutaline three times daily in 2 5 year old children with asthma
Pediatric Pulmonology, 2000Co-Authors: Anna‐leena Kuusela, Marianne Marenk, Grazyna Sandahl, Jon Sanderud, Kari Nikolajev, Bengt PerssonAbstract:The aim of this study was to compare safety and efficacy of Bambuterol hydrochloride (10 mg) oral solution administered once daily in the evening with terbutaline sulphate (0.075 mg/kg body weight) oral solution administered three times daily in 2-5-year-old children with asthma. There were two treatment groups: (2/3) of the patients received Bambuterol and (1/3) received terbutaline. The study was double-blind, randomized, and of a parallel group design, and it lasted for 3 months after a 2-week run-in period. The primary objective was to evaluate safety (adverse events, and changes in blood pressure, pulse rate, hematology, and clinical chemistry parameters). Plasma concentrations of terbutaline and/or Bambuterol were also measured. Evaluation of efficacy (diary card data) was a secondary objective. A total of 155 patients (range, 2-6 years; 3 patients were 6 years old at randomization) were treated with the study drugs; 104 patients received Bambuterol and 51 patients received terbutaline. Both treatments showed a good safety profile with respect to clinical and laboratory tests, and they were generally well tolerated. Reported adverse events were mild to moderate. There were no statistically significant differences between treatment groups in any of the efficacy variables (diary variables: peak expiratory flow (PEF), asthma symptoms, restlessness, other reported symptoms, use of inhaled bronchodilators, and nighttime awakenings). For morning PEF, the mean increase from run-in to treatment was 16.9 L/min in the terbutaline group and 23.3 L/min in the Bambuterol group. For evening PEF, the mean increase was 20.2 L/min in the terbutaline group and 20.6 L/min in the Bambuterol group. In conclusion, once-daily Bambuterol is as safe and effective as terbutaline given three times daily. The study also confirmed that Bambuterol has a 24-hr duration of action, and therefore its once daily administration, makes it a preferred bronchodilator agent. Pediatr Pulmonol. 2000:29:194-201.
-
Comparative study using oral solutions of Bambuterol once daily or terbutaline three times daily in 2–5‐year‐old children with asthma
Pediatric pulmonology, 2000Co-Authors: Anna‐leena Kuusela, Marianne Marenk, Grazyna Sandahl, Jon Sanderud, Kari Nikolajev, Bengt PerssonAbstract:The aim of this study was to compare safety and efficacy of Bambuterol hydrochloride (10 mg) oral solution administered once daily in the evening with terbutaline sulphate (0.075 mg/kg body weight) oral solution administered three times daily in 2-5-year-old children with asthma. There were two treatment groups: (2/3) of the patients received Bambuterol and (1/3) received terbutaline. The study was double-blind, randomized, and of a parallel group design, and it lasted for 3 months after a 2-week run-in period. The primary objective was to evaluate safety (adverse events, and changes in blood pressure, pulse rate, hematology, and clinical chemistry parameters). Plasma concentrations of terbutaline and/or Bambuterol were also measured. Evaluation of efficacy (diary card data) was a secondary objective. A total of 155 patients (range, 2-6 years; 3 patients were 6 years old at randomization) were treated with the study drugs; 104 patients received Bambuterol and 51 patients received terbutaline. Both treatments showed a good safety profile with respect to clinical and laboratory tests, and they were generally well tolerated. Reported adverse events were mild to moderate. There were no statistically significant differences between treatment groups in any of the efficacy variables (diary variables: peak expiratory flow (PEF), asthma symptoms, restlessness, other reported symptoms, use of inhaled bronchodilators, and nighttime awakenings). For morning PEF, the mean increase from run-in to treatment was 16.9 L/min in the terbutaline group and 23.3 L/min in the Bambuterol group. For evening PEF, the mean increase was 20.2 L/min in the terbutaline group and 20.6 L/min in the Bambuterol group. In conclusion, once-daily Bambuterol is as safe and effective as terbutaline given three times daily. The study also confirmed that Bambuterol has a 24-hr duration of action, and therefore its once daily administration, makes it a preferred bronchodilator agent. Pediatr Pulmonol. 2000:29:194-201.
-
One-year safety study with Bambuterol once daily and terbutaline three times daily in 2–12-year-old children with asthma
Pediatric pulmonology, 2000Co-Authors: Jasminka P. Zarkovic, Anna‐leena Kuusela, Marianne Marenk, Grazyna Sandahl, Erkka Valovirta, Bengt PerssonAbstract:The aim of this study was to compare Bambuterol oral solution (10 mg) administered once daily in the evening with terbutaline oral solution (0.075 mg/kg body weight) administered three times daily in 2–5-year-old children and to compare Bambuterol tablets (10 mg or 20 mg) administered once daily in the evening with terbutaline tablets (2.5 mg) administered three times daily in 6–12-year-old children with asthma. The study was of an open, randomized, parallel-group design, and lasted 1 year. The primary objective was to evaluate safety (pulse rate, blood pressure, adverse events, hematology, and clinical chemistry). Plasma terbutaline concentrations were also measured. Evaluation of efficacy (FEV1) was a secondary objective. A total of 141 patients (83 boys, 58 girls) were randomized and treated with the study drugs, i.e., 43 patients in the terbutaline group (30 on oral solution and 13 on tablets) and 98 patients in the Bambuterol group (62 on oral solution and 36 on tablets). A total of 11 patients discontinued the study: 3 were on terbutaline, and 8 were on Bambuterol. There were no clinically important differences between treatment groups regarding pulse rate, or systolic or diastolic blood pressure. There were no clinically important findings in the laboratory tests (hematology and clinical chemistry). Both terbutaline and Bambuterol were well-tolerated, and the reported adverse events were mostly mild or moderate. Mean steady state plasma terbutaline concentrations at the visits ranged between 8.0–11.5 nmol/L in the Bambuterol tablet group and between 10.6–15.2 nmol/L in the terbutaline tablet group. The corresponding values in children on oral solution were 10.3–11.3 nmol/L in the Bambuterol group and 7.5–9.7 nmol/L in the terbutaline group. FEV1 measured in the 6–12-year-old children increased by more than 0.2 L in both treatment groups during the year in the study. In conclusion, Bambuterol tablets or oral solution once daily and terbutaline tablets or oral solution three times daily showed a comparable and favorable safety profile. Pediatr Pulmonol. 2000; 29:424–429. © 2000 Wiley-Liss, Inc.
Ting Zhou - One of the best experts on this subject based on the ideXlab platform.
-
Design, synthesis and biological evaluation of Bambuterol analogues as novel inhibitors of butyrylcholinesterase.
European journal of medicinal chemistry, 2016Co-Authors: Yiguang Tian, Marco Pistolozzi, Shanping Wang, Ya Jin, Ting Zhou, Gaurab Roy, Wen TanAbstract:An increase activity of butyrylcholinesterase is believed to contribute to Alzheimer's disease. Bambuterol is a known potent inhibitor of butyrylcholinesterase, but it has undesired cardiac effects and less lipophilicity. Thirteen Bambuterol analogues were synthesized using 1-(3, 5-dihydroxyphenyl) ethanone as a starting material. In-vitro cholinesterase assay established that the majority of the compounds are specific butyrylcholinesterase inhibitors. Out of the 13 compounds, two Bambuterol derivatives, BD-6 and BD-11 exhibited similar efficacies in inhibiting butyrylcholinesterase with fewer effects on heart and enhanced possibilities of permeating through the blood-brain barrier as compared to Bambuterol. These Bambuterol analogues may provide better alternatives for treatments of Alzheimer's disease.
-
In vivo metabolism study of (R)-Bambuterol in humans using ultra high performance liquid chromatography with tandem mass spectrometry.
Journal of separation science, 2016Co-Authors: Ting Zhou, Shan Liu, Ting Zhao, Dan Zeng, Yang Yang, Wen TanAbstract:(R)-Bambuterol, a selective β2-adrenoceptor agonist, has been approved as a new drug for the treatment of asthma and chronic obstructive pulmonary disease by the China Food and Drug Administration and is currently under phase I clinical trials. In this study, a combined method based on ultra high performance liquid chromatography with triple quadrupole mass spectrometry and ultra high performance liquid chromatography with quadrupole time-of-flight mass spectrometry was employed for the identification of the major metabolites of (R)-Bambuterol in human plasma and urine after an oral dose of 10 mg. The metabolites were separated by gradient elution program and different sample preparation methods were compared. Totally, 12 metabolites of (R)-Bambuterol were identified, including four metabolites in plasma and all 12 metabolites in urine. Among these, four metabolites are reported for the first time. The possible metabolic pathways of (R)-Bambuterol were subsequently proposed. The results indicated that (R)-Bambuterol was metabolized via hydrolysis, demethylation, oxygenation, glucuronidation, and sulfation pathways in vivo. This study revealed that this combined method was accurate and sensitive to identify the possible metabolites and to better understand the metabolism of (R)-Bambuterol in vivo.
-
chiral analysis of Bambuterol its intermediate and active drug in human plasma by liquid chromatography tandem mass spectrometry application to a pharmacokinetic study
Journal of Chromatography B, 2015Co-Authors: Ting Zhou, Jing Zeng, Shan Liu, Ting Zhao, Wen TanAbstract:Abstract A sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) method has been developed for simultaneous chiral analysis of an antiasthma drug Bambuterol, its key intermediate monocarbamate Bambuterol and its active drug terbutaline in human plasma. All samples were extracted with ethyl acetate and separated on an Astec Chirobiotic T column under isocratic elution with a mobile phase consisting of methanol and water with the addition of 20 mm ammonium acetate and 0.005% (v/v) formic acid at 0.6 mL/min. The analytes were detected by a Xevo TQ-S tandem mass spectrometer with positive electrospray ionization in multiple reaction monitoring mode. The established method has high sensitivity with the lower limit of quantifications of 25.00 pg/mL for Bambuterol enantiomers, and 50.00 pg/mL for monocarbamate Bambuterol and terbutaline enantiomers, respectively. The calibration curves for Bambuterol enantiomers were linear in the range of 25.00–2500 pg/mL, and for monocarbamate Bambuterol and terbutaline enantiomers were linear in the range of 50.00–5000 pg/mL. The intra- and inter-day precisions were
-
Chiral analysis of Bambuterol, its intermediate and active drug in human plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study
Journal of chromatography. B Analytical technologies in the biomedical and life sciences, 2015Co-Authors: Ting Zhou, Jing Zeng, Shan Liu, Ting Zhao, Wen TanAbstract:Abstract A sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) method has been developed for simultaneous chiral analysis of an antiasthma drug Bambuterol, its key intermediate monocarbamate Bambuterol and its active drug terbutaline in human plasma. All samples were extracted with ethyl acetate and separated on an Astec Chirobiotic T column under isocratic elution with a mobile phase consisting of methanol and water with the addition of 20 mm ammonium acetate and 0.005% (v/v) formic acid at 0.6 mL/min. The analytes were detected by a Xevo TQ-S tandem mass spectrometer with positive electrospray ionization in multiple reaction monitoring mode. The established method has high sensitivity with the lower limit of quantifications of 25.00 pg/mL for Bambuterol enantiomers, and 50.00 pg/mL for monocarbamate Bambuterol and terbutaline enantiomers, respectively. The calibration curves for Bambuterol enantiomers were linear in the range of 25.00–2500 pg/mL, and for monocarbamate Bambuterol and terbutaline enantiomers were linear in the range of 50.00–5000 pg/mL. The intra- and inter-day precisions were
-
The Lipid-lowering Effects of R-Bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study.
EBioMedicine, 2015Co-Authors: Lei Quan, Ting Zhou, Long Zhu, Jing Zeng, Chengjuan Zou, Qing Cheng, Wen TanAbstract:Background Existing treatments are inadequate for patients at high risk of coronary heart disease caused by elevated levels of plasma low-density lipoprotein cholesterol (LDL-C). Bambuterol is a prodrug of β2-agonist commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) with the advantage of once daily dosing and favorable side effect profile. The potential lipid-lowering effects of Bambuterol were unclear, possibly due to the racemic Bambuterol (rac-Bambuterol) that was used in previous studies.
Mohamed Ibrahim Halawa - One of the best experts on this subject based on the ideXlab platform.
-
Amplified anodic electrogenerated chemiluminescence of tris(2,2′-bipyridyl)ruthenium(II) for ultrasensitive detection of Bambuterol: Application to content uniformity testing
Journal of Electroanalytical Chemistry, 2021Co-Authors: Mohamed Ibrahim Halawa, Islam M. MostafaAbstract:Abstract Asthma is one of the most common chronic diseases among children and has affected about 300 million individuals worldwide according to the report of the world health organization. Herein, we present the first electrochemiluminescence (ECL) report for the determination of an important antiasthmatic drug (Bambuterol). It was found that Bambuterol can act as an efficient coreactant for Ru(bpy)32+ ECL via oxidation-reduction pathway. The electrogenerated reducing species from Bambuterol and Ru(bpy)32+ could react together at the surface of gold electrode to generate an intense ECL signal. Based on this new finding, the first ECL study was proposed and optimized for the rapid, highly sensitive, and selective screening of Bambuterol in its pure form with a wide linearity of 10.0 nM - 2.0 μM and an ultra-low detection limit of 1.48 nM. The developed system was applied for assaying Bambuterol in pharmaceutical preparations. Furthermore, the developed system was also utilized to determine the content uniformity of Bambuterol in low dose tablets.
-
amplified anodic electrogenerated chemiluminescence of tris 2 2 bipyridyl ruthenium ii for ultrasensitive detection of Bambuterol application to content uniformity testing
Journal of Electroanalytical Chemistry, 2021Co-Authors: Mohamed Ibrahim Halawa, Islam M. MostafaAbstract:Abstract Asthma is one of the most common chronic diseases among children and has affected about 300 million individuals worldwide according to the report of the world health organization. Herein, we present the first electrochemiluminescence (ECL) report for the determination of an important antiasthmatic drug (Bambuterol). It was found that Bambuterol can act as an efficient coreactant for Ru(bpy)32+ ECL via oxidation-reduction pathway. The electrogenerated reducing species from Bambuterol and Ru(bpy)32+ could react together at the surface of gold electrode to generate an intense ECL signal. Based on this new finding, the first ECL study was proposed and optimized for the rapid, highly sensitive, and selective screening of Bambuterol in its pure form with a wide linearity of 10.0 nM - 2.0 μM and an ultra-low detection limit of 1.48 nM. The developed system was applied for assaying Bambuterol in pharmaceutical preparations. Furthermore, the developed system was also utilized to determine the content uniformity of Bambuterol in low dose tablets.
